Mohammad AskarPublic working copy · medical review pending

Uveitis emergencies · 166

Uveitis emergencies: recognise infection and visual threat

Assess acuity, inflammation, pressure, retina and immune status immediately. A quiet eye can conceal destructive retinitis.

Public working copy · medical review pending. Source, translation and medical checks remain open. Read the limitations in the text and references. These educational materials do not replace individual medical assessment. Published: 2026-11-18T19:45:52+01:00. Internal project references lead to this notice. They are not publicly accessible primary sources; the source limitations remain stated in the text.

Clinical suspicion can require treatment before laboratory confirmation. Separate infectious necrosis from immune-mediated inflammation before selecting steroids and immunosuppression.

Terminology and draft status

Terminology review is not complete. Selected actual WHO UMD queries and their limits are recorded in terminology.md; they do not approve the whole translation.

01Triage, examination and targeted tests

The original distinction between “symptomatic” red painful photophobic eyes and “functional” visual-loss emergencies is a teaching framework, not a safe low-risk triage rule. Severe pain can signal keratitis, pressure crisis or infection, while sight-threatening retinitis may cause little redness. Assess visual function and anatomy rather than reassurance from symptoms alone. 1

Ask whether this is a first episode or known relapse, and about systemic disease, HIV, transplantation, chemotherapy and immunosuppressants. Measure vision, slit-lamp inflammation and IOP, inspect the dilated retina and select imaging/tests for the differential. Young working adults can be severely affected, but age does not determine urgency. 1

The exported blood count, chest X-ray, PPD/QuantiFERON, ACE, syphilis serology, electrolytes and liver tests are an investigation menu, not an obligatory panel or exclusion tests. Select the clinical question; negative TB testing does not exclude ocular TB, and raised ACE does not establish sarcoidosis. Plan renal/liver/blood monitoring when systemic treatment requires it. 1

02Recognise ARN, PORN and CMV

ARN combines peripheral necrotising retinitis, circumferential spread and occlusive arteritis, often with anterior/vitreous inflammation. HSV/VZV and immune status matter; immune competence is not a required diagnostic condition. Retinal detachment is an important complication; the original “up to 75%” is a cohort-dependent maximum, not an individual prediction. 1

Obtain appropriate ocular PCR without delaying treatment. The AAO report included 33 retrospective studies; it supports initial systemic oral or IV antivirals and possible adjunct intravitreal foscarnet, not a universal IV-only regimen. The original aciclovir 10 mg/kg three times daily is a source example requiring renal/dose monitoring. ARN urgency resembles endophthalmitis, but the drug pathway is antiviral, not automatically the same antibacterial protocol. Avoid unopposed intraocular/systemic steroids; the original 48-hour start is not universal. 1 6

PORN typically occurs with profound immune impairment, often CD4 <50 cells/µL, with rapid outer-retinal necrosis, posterior/macular involvement and little inflammation; CMV can also look quiet. Neither absence of vitritis nor a “pizza/ketchup” haemorrhagic appearance is obligatory. PORN needs urgent specialist systemic/intravitreal antiviral selection and immune care, not automatic substitution of valganciclovir for every VZV case. 1

CMV retinitis in HIV requires direct anti-CMV treatment plus ART/immune management, not ART alone. Systemic valganciclovir or IV ganciclovir is selected by circumstances, with intravitreal treatment added for immediately sight-threatening lesions. Stopping maintenance requires inactive lesions, at least 3 months of anti-CMV therapy and CD4 ≥100 for at least 3 months on ART with ophthalmic agreement; continue relapse/IRU surveillance. These HIV criteria do not automatically apply to transplant recipients. 1 3

The source associates HSV-2 with ages 20–30 and VZV with 50–60, but these are tendencies rather than pathogen-by-age rules. Redness, floaters and rapid decline can reach no light perception (NLP). Fellow-eye involvement about 30%, detachment up to 75% and prophylactic valacyclovir about 1 year are source-dependent; counsel about later immune suppression and relapse without fixed personal probabilities or duration. 1

PORN often begins posteriorly with rapidly spreading outer-retinal necrosis and little inflammatory response in profound immune impairment; “exclusively” is too absolute. The original blindness within 1 month and 50% mortality within 5 months are untraced historical claims, not contemporary individual forecasts under effective antiviral/immune care. HAART/ART reduces CMV incidence but can be followed by immune recovery uveitis (IRU), requiring assessment rather than assuming recurrent infection. 1

Recognise ARN, PORN and CMV
FeatureARNPORN
InflammationOften marked anterior/vitreous inflammationOften little inflammation in profound immune impairment
LocationOften peripheral onsetOften posterior/macular onset
ProgressionRapid, circumferential necrosis and occlusive vasculitisVery rapid outer-retinal necrosis; neither pattern is infallible
PrognosisOften better than PORN but substantial detachment/vision riskOften poor; original 1-month blindness and 5-month mortality are not universal

03Recognise toxoplasmic retinochoroiditis

A focal white necrotising lesion next to a pigmented scar with dense overlying vitritis gives the “headlight in fog” appearance, as in the original 56-year-old woman. The original 15-year-old boy has disc swelling and a macular star with a focal lesion: consider toxoplasmosis and Bartonella/cat-scratch neuroretinitis rather than declaring either image pathognomonic. 1

Juxtapapillary disease threatens the nerve; granulomatous anterior activity with mutton-fat precipitates and high IOP may reflect trabeculitis. Immunosuppression can produce multifocal/peripheral aggressive lesions. Kyrieleis segmental arterial plaques support a pattern but are not a unique pathogen test. 1

FA may show early hypofluorescent blockage and late rim staining/leakage; OCT depicts full-thickness retinal injury and EDI may show underlying choroidal thickening. Positive IgG indicates prior exposure, not proof of active ocular causation. Negative serology makes the diagnosis less likely but is not absolute exclusion in early infection or immune impairment. 1

Aqueous/vitreous PCR and intraocular antibody production, assessed with the Goldmann–Witmer coefficient, can complement the clinical diagnosis in selected atypical cases. The export’s PCR 60% and coefficient 50% sensitivities and “rarely used” claim lack protocol/population context; sampling time, immune status and prior therapy matter. 1

Toxoplasmosis may cause blur and floaters, sometimes fever, lymphadenopathy or malaise. Systemic symptoms are not required for ocular disease; their presence changes the differential and systemic investigation. 1

04Select toxoplasmosis treatment and monitor safety

Macular/nerve-threatening lesions, dense visually significant vitritis or immunosuppression favour treatment; some small peripheral disease in immunocompetent people may be observed with follow-up. The original 3–6 weeks and co-trimoxazole 960 mg twice daily plus clindamycin 300 mg four times daily are attributed regimen examples, not a universal combined first-line protocol. Check allergies, blood counts, renal function, interactions and specialist advice. 1

Pyrimethamine/sulfadiazine regimens require folinic-acid protection and laboratory monitoring. Pregnancy is not a blanket indication for “safe spiramycin or azithromycin”: gestational timing, maternal ocular disease and fetal infection are separate questions for obstetric/infectious-disease specialists. Systemic steroids, when indicated, need effective anti-parasitic coverage; the original 24–48/48-hour rule is not a precisely validated deadline for all regimens. 1

A randomised trial compared 1–3 intravitreal injections of clindamycin 1 mg/dexamethasone 400 µg with 6-week systemic pyrimethamine/sulfadiazine/prednisolone. It supports a selected local alternative, not a fixed weekly 2–3-dose rule or universal pregnancy safety; full methods and rare-harm precision remain unappraised. Local steroid with active antimicrobial is distinct from unopposed steroid injection. 1 5

05Behçet: control the sight-threatening attack and relapse risk

Recurrent oral/genital ulcers, skin lesions and pathergy support suspicion of Behçet systemic vasculitis. Panuveitis, occlusive retinal vasculitis and a hypopyon can threaten vision; hypopyon contains inflammatory cells and is not proof of pus or infection by itself. Young men along the historical Silk Road are a risk context, not an exclusion rule; HLA-B51 indicates susceptibility rather than diagnosis. 1

For sight-threatening posterior Behçet, glucocorticoids may induce rapid control alongside immunosuppressive treatment; steroid monotherapy is not durable relapse prevention. The original IV methylprednisolone 1 g is an attributed acute example, not a universal dose. Cyclosporine and monoclonal anti-TNF such as infliximab are options under specialist infection screening and systemic monitoring; EULAR recommends early effective immunosuppression for the visual threat. 1 7

06VKH: identify bilateral choroiditis and its stage

Vogt–Koyanagi–Harada (VKH) disease can involve uvea, meninges, auditory structures and skin. Flu-like fever/headache/meningism may precede ocular disease; tinnitus and later vitiligo, poliosis or alopecia can support the pattern. The source’s women aged 20–22 example does not exclude other ages or sexes. 1

Bilateral choroiditis, exudative detachments and disc hyperaemia/swelling are important; granulomatous panuveitis is not required at every stage. Ultrasound/EDI-OCT choroidal thickening and FA pinpoint leaks/late pooling (“starry sky”) help document activity but are not individually diagnostic. Treat active disease promptly with specialist anti-inflammatory/immunomodulatory care after assessing mimics and infection; severe disease may require systemic steroids rather than an imaging-only decision. 1 8

07Sympathetic ophthalmia: examine both eyes after trauma or surgery

Sympathetic ophthalmia is a rare bilateral inflammatory disease after penetrating injury or intraocular surgery in one eye. The fellow “sympathising” eye may develop granulomatous panuveitis resembling VKH; history and exclusion of infection/other causes are essential. Urgent specialist immunosuppression can be needed to preserve vision. 1

Do not convert the original prevention claim into routine enucleation of a blind injured eye. The 2026 RCOphth open-globe recommendation limits primary removal to eyes not technically repairable; its cited meta-analysis does not establish a clear preventive advantage for routine removal. Assess repairability, pain, visual potential and patient preference separately, and do not delay treatment of established fellow-eye inflammation while considering eye removal. 1 9

Sympathetic ophthalmia: examine both eyes after trauma or surgery
DiseasePatient contextKey findingsCauseUrgent management
ARNAny relevant immune statusPeripheral spreading necrosis, occlusive arteritisHSV/VZVSystemic oral/IV antivirals, selected intravitreal adjunct; monitor kidney
PORNProfound immune impairmentRapid posterior/outer necrosis with little inflammationUsually VZVUrgent pathogen-matched systemic/intravitreal treatment and immune care
CMV retinitisOften HIV/CD4 <50, not exclusivelyNecrotising ±haemorrhagic lesions, often little vitritisCMVDirect systemic anti-CMV plus selected local treatment and ART/immune care
ToxoplasmosisImmune competent or impairedFocal retinochoroiditis with vitritis, sometimes old scarToxoplasma gondiiSelected antiparasitic therapy; steroid only with effective coverage, not a universal triple protocol
BehçetOften younger Silk Road patients; not exclusiveUlcers, panuveitis, occlusive vasculitis, hypopyonImmune-mediated vasculitisRapid control plus effective immunosuppression, not steroid monotherapy
VKHAge/sex do not excludeBilateral choroiditis, exudative detachment, auditory/skin/neurological cluesImmune-mediatedPrompt specialist systemic anti-inflammatory/immunomodulatory care
Sympathetic ophthalmiaPrior penetrating injury/intraocular surgeryBilateral granulomatous inflammation resembling VKHImmune-mediated after injuryUrgent specialist care; routine prophylactic enucleation not established
What distinguishes an infectious emergency?

Clinical suspicion can require treatment before laboratory confirmation. Separate infectious necrosis from immune-mediated inflammation before selecting steroids and immunosuppression.

When is assessment urgent?

Rapid visual loss, new floaters with retinitis, severe pain or photophobia, marked pressure rise or suspected infection during immune suppression needs urgent ophthalmic assessment.

References and access status

  1. 1
    Immutable original export; emergency lecture attributed to Hassan Al-Dhibi

    Complete export read; original attribution and any recording/transcript or appointment not independently verified.

  2. 2
    CDC ocular/neurosyphilis treatment guidance

    Full short page read 15 November 2026; linked evidence and local labels unread.

  3. 3
    NIH HIV CMV disease, 2025 update / 2026 review

    Selected CMV retinitis manifestations/diagnosis and treatment/stop-maintenance sections read 15 November 2026; not every systemic section or underlying trial.

  4. 4
    BTS ocular TB clinical statement 2022

    Selected actual indexed diagnostic/IGRA/TST and treatment-duration text read 15 November 2026; not whole statement or every study.

  5. 5
    Soheilian et al. randomised IV clindamycin/dexamethasone trial

    Selected indexed original design/regimen text read 15 November 2026; complete report/outcome tables/supplements unread.

  6. 6
    AAO ARN evidence report 2017

    Complete PubMed abstract read 15 November 2026:33 retrospective studies; full report/supplements unread.

  7. 7
    EULAR Behçet recommendations:2025 update, published2026

    Historical Review 033 selected access of 7 November 2026 reused; full current reports/every primary study not read anew.

  8. 8
    SUN classification: Vogt–Koyanagi–Harada disease

    Historical Review 033 selected access of 7 November 2026 reused; full current reports/every primary study not read anew.

  9. 9
    RCOphth open-globe injury guideline 2026: primary removal

    Actual indexed selected primary-removal recommendation read 15 November 2026; complete guideline and referenced meta-analysis not fully appraised.